The 3 Best Gene Editing Stocks on the Frontier of Medicine
Published
Here are three of the top gene editing stocks to own heading into 2024 Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease ( ) from CRISPR Therapeutics (NASDAQ:CRSP), a move that could…
#usfda #crisprtherapeutics #crsp #nationalheart #bloodinstitute #editasmedicine #ruby #edithal #edit #q3eps